

May 26, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Intimation of Schedule of Earnings Conference Call on Q4FY25/FY25 Results

Ref.: Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our earlier intimation dated May 22, 2025, regarding a meeting of the Board of Directors of Zota Health Care Limited (the “Company”) is scheduled to be held on May 29, 2025 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that following the announcement of the Audited standalone and consolidated Financial Results of the Company for the quarter and year ended March 31, 2025, the Company will host an Earnings Calls on Friday, May 30, 2025 at 11:30 A.M. (IST).

The conference call invitation is enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Zota Healthcare Limited to announce Q4FY25/FY25 Results on 29th May 2025; Earnings Call to be held at 11:30 AM IST on 30th May 2025 (Friday)

Surat, 26th May 2025: Zota Health Care Limited, one of the leading pharmaceutical companies with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, will announce Audited financial results for the Fourth quarter & Full year FY25 period ended 31st March 2025 on 29th May 2025. **Following the announcement, the management of the Company will host an Earnings Call on Friday, 30th May 2025 at 11:30 AM (IST).**

The Details are:

Date:	Friday, May 30, 2025
Time:	11:30 hrs. IST
Duration:	60 minutes
Dial-in Details:	<i>Participants are encouraged to dial in 10 minutes prior to the call start time to avoid last-minute hold times. If you reach an operator during the dial-in process, please inform them that you would like to join the “Zota Healthcare Limited Q4FY25 Earnings Conference Call”.</i>
Universal Access numbers	+91 22 6280 1107 +91 22 7115 8008
Pre-Registration Facility	<ul style="list-style-type: none">• Step 1: Pre-register here. You will receive an email confirmation with the call details on the registered email address.• Step 2: Dial into the call on the Conference Call date, you will be directly connected to the call.

Management Representation from Zota Healthcare Limited

Mr. Himanshu Zota, Founder and Whole Time Director

Mr. Moxesh Zota, Managing Director

Dr. Sujit Paul, Group Chief Executive Officer

About Zota Health Care Limited:

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 470 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com

For details please contact:

Mr. Ashvin Variya

CS, Zota Health Care Ltd

E: cszota@zotahealthcare.com

Mr. Siddesh Chawan

Ernst & Young LLP, Investor Relations

E: Siddesh.Chawan@in.ey.com

Mr. Ajit Mishra

Ernst & Young LLP, Investor Relations

E: Ajit.J.Mishra@in.ey.com
